Calcium Metabolism in Adults With Severe Aortic Valve Stenosis and Preserved Renal Function

American Journal of Cardiology

Volumn 105, Issue 6, 2010, Pages 862-864

  Akat, Kemal ^a   Kaden, Jens Johannes ^a   Schmitz, Fabian ^b,c   Ewering, Silke ^b   Anton, Anja ^a   Klomfaß, Sebastian ^b   Hoffmann, Rainer ^b   Ortlepp, Jan Rudolf ^b,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c St Antonius Hospital   (Germany)

^d Clinic for Internal Medicine and Intensive Care   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; AORTA VALVE STENOSIS; ARTICLE; BONE METABOLISM; CALCIUM METABOLISM; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; AORTIC VALVE STENOSIS; CALCIUM; CHOLECALCIFEROL; CREATININE; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATES;

EID: 77649338364     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.065     Document Type: Article

References (27)

1. Rajamannan N.M. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 29 (2009) 162-168
2. Bosse Y., Mathieu P., and Pibarot P. Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 51 (2008) 1327-1336
3. Helske S., and Otto C.M. Lipid lowering in aortic stenosis: still some light at the end of the tunnel?. Circulation 119 (2009) 2653-2655
4. Ortlepp J.R., Hoffmann R., Ohme F., Lauscher J., Bleckmann F., and Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 85 (2001) 635-638
5. Ortlepp J.R., Schmitz F., Mevissen V., Weiss S., Huster J., Dronskowski R., Langebartels G., Autschbach R., Zerres K., Weber C., Hanrath P., and Hoffmann R. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 25 (2004) 514-522
6. Mills W.R., Einstadter D., and Finkelhor R.S. Relation of calcium-phosphorus product to the severity of aortic stenosis in patients with normal renal function. Am J Cardiol 94 (2004) 1196-1198
7. Ortlepp J.R., Pillich M., Schmitz F., Mevissen V., Koos R., Weiss S., Stork L., Dronskowski R., Langebartels G., Autschbach R., Brandenburg V., Woodruff S., Kaden J.J., and Hoffmann R. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. J Heart Valve Dis 15 (2006) 502-508
8. Linhartová K., Veselka J., Sterbakova G., Racek J., Topolcan O., and Cerbak R. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 72 (2008) 245-250
9. Maher E.R., Young G., Smyth-Walsh B., Pugh S., and Curtis J.R. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2 (1987) 875-877
10. Cohen J.L., Barooah B., Segal K.R., and Batuman V. Two-dimensional echocardiographic findings in patients on hemodialysis for more than six months. Am J Cardiol 60 (1987) 743-745
11. Straumann E., Meyer B., Misteli M., Blumberg A., and Jenzer H.R. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 67 (1992) 236-239
12. Kume T., Kawamoto T., Akasaka T., Watanabe N., Toyota E., Neishi Y., Wada N., Okahashi N., and Yoshida K. Rate of progression of valvular aortic stenosis in patients undergoing dialysis. J Am Soc Echocardiogr 19 (2006) 914-918
13. O'Neill W.C. The fallacy of the calcium-phosphorus product. Kidney Int 72 (2007) 792-796
14. Stefenelli T., Mayr H., Bergler-Klein J., Globits S., Woloszczuk W., and Niederle B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 95 (1993) 197-202
15. Hass G.M., Trueheart R.E., and Hemmens A. Experimental arteriosclerosis due to hypervitaminosis D. Am J Pathol 37 (1960) 521-549
16. Drolet M.C., Arsenault M., and Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 41 (2003) 1211-1217
17. Holick M.F. Sunlight and vitamin D: both good for cardiovascular health. J Gen Intern Med 17 (2002) 733-735
18. Jono S., Nishizawa Y., Shioi A., and Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98 (1998) 1302-1306
19. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40 (2007) 1434-1446
20. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., and Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32 (2003) 681-686
21. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., and Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106 (2002) 1192-1194
22. Ziegler S., Kudlacek S., Luger A., and Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182 (2005) 175-180
23. Golledge J., McCann M., Mangan S., Lam A., and Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 (2004) 1636-1641
24. Helske S., Kovanen P.T., Lindstedt K.A., Salmela K., Lommi J., Turto H., Werkkala K., and Kupari M. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 9 (2007) 357-363
25. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoc A., Kilic R., Brueckmann M., Lang S., Zahn I., Vahl C., Hagl S., Dempfle C.E., and Borggrefe M. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004) 57-66
26. Van Campenhout A., and Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204 (2009) 321-329
27. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., and Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268